Trial
NCT04849273
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Turning Point Therapeutics, Inc.
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
TPX-0131
Why stopped
Adverse change in the risk/benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-26